<DOC>
	<DOC>NCT02615496</DOC>
	<brief_summary>The study will be an observational, cross-sectional study of knowledge, understanding, and self-reported behavior among a sample of physicians and patients with recent aflibercept experience in a total of up to five European countries.</brief_summary>
	<brief_title>Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Physicians eligibility: Licensed and practicing ophthalmologist Prescribed and administered aflibercept to at least one patient in the past 6 months Patients eligibility: Patient has been administered aflibercept at least once within the last 6 months for any indication and is returning for a subsequent visit. Patient is aged 18 years or older. Patient is able to understand and sign the consent form and patient questionnaire. Patient can understand the native language of the country in which the study is being conducted. Patient has not participated in a clinical trial for the treatment of an aflibercept indication (e.g., wAMD, CRVO, or DME) in the past 12 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Health Care Surveys</keyword>
	<keyword>Vascular Endothelial Growth Factor</keyword>
</DOC>